Exhibit 10.3
LABORATORY SERVICE
AGREEMENT
This Laboratory Service Agreement
(“Agreement”) is effective as of November 22, 2005
(“Effective Date”), by and between Covance Central
Laboratory Services LP (“Covance”) , an
Indiana limited partnership, with offices at 8211 SciCor Drive,
Indianapolis, Indiana 46214, and Advanced Life Sciences Inc.
(“ALSI”), with offices at 1440 Davey Road, Woodridge,
IL 60517.
Recitals
WHEREAS, Covance is engaged in the business of
providing laboratory testing, data management, protocol management
and information management services for pharmaceutical clinical
trials (“Services”); and
WHEREAS, ALSI desires for Covance to perform
such Services in accordance with and subject to the terms and
conditions of this Agreement.
NOW, THEREFORE, in consideration of the
foregoing recitals and the mutual promises and covenants contained
herein, and each act done pursuant thereto, ALSI and Covance agree
as follows:
1.
DEFINITIONS AND
INTERPRETATION
(a) Definitions - The following
terms, as used herein (unless a clear contrary interpretation
appears), have the following meanings:
“Clinical Trial” means a Study or
the scientific evaluation of a Drug or Medical Device on the terms
and conditions of a Protocol.
“Drug” means a new or existing
drug provided by ALSI and which is the subject of a Clinical Trial
or Study under this Agreement.
“FDA” means the United States Food
and Drug Administration or any other government body or agency that
succeeds it.
“Project” means a Study or Clinical
Trial, or any other clinical trial, project or assignment between
Covance and ALSI.
“Protocol” means the document which
specifies the laboratory testing procedures as written by ALSI as
applicable for the performance of a Study or Clinical Trial and is
provided to Covance.
“Study” means a Clinical Trial or
the scientific evaluation of a Drug or Medical Device on the terms
and conditions of the Protocol.
(b)
Interpretation
- In this Agreement, unless a clear
contrary intention appears:
i.
the singular number includes the
plural and vice versa ;
1
ii.
reference to any person or entity
includes such person’s or entity’s successors and
assigns;
iii.
reference to this Agreement means
such agreement as amended, modified or supplemented from time to
time in accordance with the terms hereof;
iv.
reference to any law, rule,
regulation, order, decree, requirement, policy, guideline,
directive or interpretation means as amended, modified, codified,
replaced or reenacted in whole or in part, and in effect on the
determination date, including rules and regulations
promulgated thereunder;
v.
“hereunder”,
“hereof”, “hereto” and words of similar
import shall be deemed references to this Agreement as a whole and
not to any particular Section or other provision
hereof;
vi.
“including” (and with
correlative meaning “include”) means including without
limiting the generality of any description preceding such term;
and
vii.
relative to the determination of any
period of time, “from” means “from and including
to” and “to” means “to but
excluding”.
2.
SERVICES
Covance hereby agrees to perform Services for
ALSI’s protocol
,
pursuant to the terms and conditions contained in this Agreement,
the Protocol, the Statement of Work (“SOW”), the Quote
for Services (“Budget”), and all other applicable
documents.
3.
FEES AND
BILLING
Fees for the Project are set forth in the
attached Budget. The Budget contains all of the applicable
discounts and Services that will be provided for that
Project.
ALSI agrees make an advance payment equal to 10%
of the Budget (“Advance Payment”). Covance will
invoice the Advance Payment when this Agreement has been signed by
both parties. ALSI will pay the Advance Payment invoice
within thirty (30) days after receipt.
Each month, Covance will invoice ALSI for all
fees due and expenses incurred while providing Services during the
previous month. Payment is due thirty (30) days from the date
of the invoice. After invoices have reached 90% of the
Budget, Covance will begin applying funds from the Advance Payment
to the monthly invoices. Should the Study be terminated
before the Advance Payment is exhausted, and assuming all prior
invoices have been paid, Covance will apply Advance Payment funds
to the final invoice and refund any remaining Advance Payment funds
to ALSI within thirty (30) days.
Upon written notification by ALSI that the
Clinical Trial has been concluded or six months after the
non-receipt of any kits (whichever comes first), Covance will issue
a final invoice for any Services rendered to identify amounts due
to Covance or refund due to ALSI.
2
Covance will hold prices unchanged for twelve
(12) months from Project start up. Thereafter, fees may be
adjusted annually by Covance upon thirty (30) days written notice
to ALSI. However, should global political, logistical or
economic changes take place which increase Covance’s purchase
prices, Covance may assess additional charges to ALSI upon thirty
(30) days’ prior written notice.
If ALSI requests a material change to the
Project at any time which would affect the Services, Covance will
revise fees to reflect the change in the SOW and/or
Budget.
COVANCE will provide each Investigator site with
project and visit specific specimen collection supplies needed to
collect and ship specimens. The kits include test tubes, pipettes,
collection needles, and other required materials, in addition to
instructions for collection and shipment. The kits shall also have
a test requisition form designated for the Project. Each kit and
collection tube will be bar coded to ensure tracking and testing
audit trails upon its return to Covance. Should a kit be lost
through no fault of Covance, or should a kit expire at the
Investigator site, or should a kit otherwise need to be replaced
through no fault of Covance, Covance will supply replacement kits
for those that need to be replaced. The charge for any
replacement kit which is lost, expires, or otherwise needs to be
replaced through no fault of Covance, will be an amount equal to
the price listed in the Budget per kit for the same kit/visit as is
being replaced.
4.
PROPERTY
OWNERSHIP
All materials, documents, information, programs
and suggestions of every kind and description supplied to Covance
by or on behalf of ALSI or prepared or developed by Covance
pursuant to this Agreement (except for Covance procedural manuals,
personnel data and Covance developed technology and software) shall
be the sole and exclusive property of ALSI. Strategic insight
and proposed Project design and scope provided in any Covance
proposal shall remain the property of Covance and may only be used
by ALSI to assess whether it wishes to pursue such work with
Covance.
5.
PATENT
RIGHTS
Covance will disclose promptly to ALSI or its
nominee any and all patentable inventions, discoveries and
improvements conceived or made by Covance in the course of the
Clinical Trial and/or while providing Services to ALSI pursuant to
this Agreement, and Covance agrees to assign all its interests
therein to ALSI or its nominee; provided ALSI requests such
assignment within one year of notification of such invention;
provided , further , that Covance shall retain all
rights to any data, processes, software (including codes),
technology, means, know-how and delta flags developed by Covance
relating to laboratory testing or data management. When
requested by ALSI, Covance will execute any and all applications,
assignments or other instruments and give testimony which ALSI
deems necessary to apply for and obtain any Letters of Patent of
the United States of America or of any foreign country or to
otherwise protect ALSI’s interest therein. ALSI shall
compensate Covance for the time devoted to said activities and
reimburse Covance for expenses incurred. These obligations
shall continue beyond the termination of this Agreement with
respect to patentable inventions, discoveries and improvements
conceived or made by Covance while providing Services to ALSI
pursuant to this Agreement, and shall be binding upon
Covance’s assignees.
3
6.
CONFIDENTIAL INFORMATION/LEGAL
PROCEEDINGS
Covance agrees that all materials, documents and
information provided to it by ALSI and, except as provided in
Section 4, all test information, data and records developed by
Covance exclusively in connection with the performance of its
Services pursuant to this Agreement is and shall be the sole
property of ALSI and considered confidential (collectively,
“Confidential Information”). Covance agrees to
hold Confidential Information in confidence and in a manner
consistent with the way in which Covance maintains the
confidentiality of its own proprietary information. Covance
shall disclose the Confidential Information to Investigators and
Covance employees, officers, directors and representatives only on
a need-to-know basis. Covance agrees that, except as
necessary to fulfill its obligations under this Agreement, it will
not use or disclose to any other third party any Confidential
Information; provided , however , that Covance has no
obligations with respect to any Confidential Information that
is:
(a)
now or later becomes publicly
available through no fault of Covance;
(b)
obtained by Covance from a third
party not under obligation to ALSI with respect to such
Confidential Information;
(c)
already in Covance’s
possession as indicated in its written records; or
(d)
required to be disclosed by any law,
rule, regulation, order, decree or subpoena, in which event Covance
will give ALSI, if practicable, advance written notice to permit
ALSI to seek a protective order or other similar order with respect
to such Confidential Information.
The foregoing obligations of non-use and
confidentiality will extend for five (5) years beyond the date
of disclosure or generation of such Confidential
Information.
Should Covance be obligated to provide testimony
or records regarding any Study, Protocol or Clinical Trial in any
legal or administrative proceeding, then ALSI shall reimburse
Covance its out-of-pocket costs therefore plus an hourly fee for
its employees or representatives equal to the internal fully
burdened cost to Covance of such employee or
representative.
Nothing contained in this Section 6 shall
be interpreted to limit the rights and obligations of the parties
under Section 4 hereof and to the extent that any conflict
arises in applying the provisions of Sections 4 and 6, the
provisions of Section 4 shall control.
7.
COMPLIANCE
Performance - Covance will perform its Services
in accordance with the current state of the laboratory
art.